Abada, Paolo Benjamin,Chang, Shao-Chun,Hsu, Yanzhi,Yang, Ling
申请号：
AU2015301843
公开号：
AU2015301843A1
申请日:
2015.08.11
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma in patients having levels of alpha-fetoprotein (AFP) of 1.5 ULN or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5 x ULN or greater.
